Vemlidy (Tenofovir Alafenamide)
Brand Names: Vemlidy
Methodology & AI Transparency ⓘ
Vemlidy (Tenofovir Alafenamide) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Distinguished by trade identifier Vemlidy and registered by Gilead Sciences, Inc., this hepatitis b virus nucleoside analog reverse transcriptase inhibitor product delivers active moiety Tenofovir Alafenamide (cross-referenced at /meds/tenofovir-alafenamide) (25 mg/1 Tablet; Organ-function-adjusted Vemlidy (Tenofovir Alafenamide) maintenance interval).
- 2 Real-world patient consensus: Vemlidy links directly to generic Tenofovir Alafenamide (/meds/tenofovir-alafenamide) under FDA SPL 2026-07-01 (NDC 61958-2301).
- 3 Typical cash cost range: Uninsured 30-day outlay compares $640.00 cash mean against $1696.00 retail pharmacy pricing.
- 4 Top reported side effects / signs: Primary clinical safety signals tracked in FAERS for Vemlidy (Tenofovir Alafenamide) include nausea (9.3%), headache (8.6%), dizziness (6.9%).
Ask our AI Specialists anything about Vemlidy (Tenofovir Alafenamide)
Vemlidy (Tenofovir Alafenamide) Mechanism, CYP450 Pathways & DailyMed Monograph
Distinguished by trade identifier Vemlidy and registered by Gilead Sciences, Inc., this hepatitis b virus nucleoside analog reverse transcriptase inhibitor product delivers active moiety Tenofovir Alafenamide (cross-referenced at /meds/tenofovir-alafenamide) (25 mg/1 Tablet; Organ-function-adjusted Vemlidy (Tenofovir Alafenamide) maintenance interval). Federal labeling (2026-07-01, RxCUI RXN-B619582301) defines its therapeutic scope: Federal drug listing 61958-2301 defines Tenofovir Alafenamide (manufactured/labeled by Gilead Sciences, Inc.) as a.
Inside Vemlidy, Tenofovir Alafenamide mediates hepatitis b virus nucleoside analog reverse transcriptase inhibitor pharmacodynamics with class-characteristic hepatorenal disposition across labeled adult regimens (25 mg/1 Tablet; Organ-function-adjusted Vemlidy (Tenofovir Alafenamide) maintenance interval). Commercial labeling registered by Gilead Sciences, Inc. (SPL 2026-07-01, RxNorm RXN-B619582301) pairs standardized excipient stability with federal price transparency metrics ($49.0404/unit NADAC; $1696.00 retail average).
Clinical clearance of Vemlidy (Tenofovir Alafenamide) (Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor) relies on phase i/ii hepatic conjugation of vemlidy (tenofovir alafenamide) coupled with glomerular and tubular renal excretion with a Approximately 9–16 hours terminal plasma half-life for Vemlidy (Tenofovir Alafenamide) half-life; patients absorbing at Estimated 55%–67% oral systemic absorption for Vemlidy (Tenofovir Alafenamide) bioavailability typically observe target onset around peak plasma concentration (tmax) reached 1–3 hours post-dose for vemlidy (tenofovir alafenamide).
FDA clinical labeling for Vemlidy (Tenofovir Alafenamide) restricts administration in known hypersensitivity to tenofovir alafenamide or structurally related hepatitis b virus nucleoside analog reverse transcriptase inhibitor compounds; concomitant contra-labeled cyp/transporter therapies during active vemlidy (tenofovir alafenamide) administration across 25 mg/1 Tablet, Organ-function-adjusted Vemlidy (Tenofovir Alafenamide) maintenance interval, with self-reported patient tracking dominated by nausea (9.3% of reports), headache (8.6% of reports), dizziness (6.9% of reports).
Avoid overlapping hepatitis b virus nucleoside analog reverse transcriptase inhibitor prescriptions alongside Vemlidy (Tenofovir Alafenamide) to prevent cumulative receptor toxicity.
Unstandardized herbal extracts may interact pharmacodynamically with Vemlidy (Tenofovir Alafenamide) maintenance therapy.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Known hypersensitivity to Tenofovir Alafenamide or structurally related hepatitis b virus nucleoside analog reverse transcriptase inhibitor compounds
- Concomitant contra-labeled CYP/transporter therapies during active Vemlidy (Tenofovir Alafenamide) administration
Logged Side-Effect Incidence (22 Reports)
Vemlidy (Tenofovir Alafenamide) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Vemlidy (Tenofovir Alafenamide))
Human clinical trial evidence for Vemlidy (Tenofovir Alafenamide) is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Vemlidy (Tenofovir Alafenamide) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $49.0404/unit (~$1471.21/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $1696.00 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 22 Anonymous DotMD Community Micro-Logs | $640.00 / mo | View logs ↓ |
Vemlidy (Tenofovir Alafenamide) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Vemlidy (Tenofovir Alafenamide) RxNorm Concept ID | RXN-B619582301 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $49.0404 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $1696.00 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $640.00 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 77.00% Worth It (22 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Vemlidy (Tenofovir Alafenamide) Patient Community, Cohort Filters & Dosage Logs
Deterministic Vemlidy (Tenofovir Alafenamide) reference combining NIH RxNorm (RXN-B619582301), Medicaid NADAC ($49.0404/unit), and anonymous cohort outcomes (77% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Vemlidy (Tenofovir Alafenamide) community threads and patient logs by age, biological sex, dosage, and treatment duration.